Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Drorit Grizim Merkel, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Ohad Benjamini, MD, Yaron Davidovitz, MD, Orly Goitein, MD

Blood (2019) 134 (Supplement_1): 5432.

https://doi.org/10.1182/blood-2019-125279

Published: 2019

Journal Articles

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Guy Bitansky, Elena Vasilev, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD, Meirav Kedmi, MD

Blood (2019) 134 (Supplement_1): 1534.

https://doi.org/10.1182/blood-2019-125218

Published: 2019

Journal Articles

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Yair Herishanu, MD, Adir Shaulov, MD, Riva Fineman, MD, Sandra Bašić-Kinda, MD, Ariel Aviv, MD, Ewa Wasik-Szczepanek, MD PhD, Ozren Jaksic, MD PhD, Mihnea Zdrenghea, MD, Uri Greenbaum, MD, Inga Mandac, MD, Martin Simkovic, MD PhD, Marta Morawska, MD, Ohad Benjamini, MD, Martin Spacek, MD, Anatoly Nemets, MD, Osnat Bairey, MD PhD, Andrea Visentin, MD, Rosa Ruchlemer, MD, Luca Laurenti, MD, Oana Stanca Ciocan, MD, Michael Doubek, MD PhD, Lev Shvidel, MD, Nagib Deli, MD, Fatima Miras Calvo, MD, Anne De Meûter, Maria Dimou, MD PhD, Francesca Romana Mauro, MD, Marta Coscia, MD PhD, Horia Bumbea, MD PhD, Szász Róbert, Tamar Tadmor, MD, Odit Gutwein, Massimo Gentile, Lydia Scarfo, MD, Alessandra Tedeschi, MD, Paolo Sportoletti, Eva Gimeno Vázquez, Juan Marquet Palomanes, MD, Sarit Assouline, MD, Maria Papaioannou, Andrei Breaster, MD, Luciano Levato, MD, Michael Gregor, MD, Gian Matteo Rigolin, MD, Javier Loscertales, MD, Angeles Medina Perez, MD, Marten R. Nijziel, MD PhD, Viola Maria Popov, MDPhDMSc, Rosa Collado, MD, Irma Slavutsky, Shai Levi, MSc, Aaron Polliack, MD, Paolo Ghia, MD PhD

Blood (2019) 134 (Supplement_1): 1766.

https://doi.org/10.1182/blood-2019-122309

Published: 2019

Journal Articles

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Meirav Kedmi, MD, Elena Ribakovsy, MD, Ohad Benjamini, MD, Ginette Schiby, MD, Iris Barshack, MD, Stephen P Raskin, MD, Yael Eshet, MD, Ramit Mehr, PhD, Guy Bitansky, Arnon Nagler, MD, Abraham Avigdor, MD

Blood (2018) 132 (Supplement 1): 4186.

https://doi.org/10.1182/blood-2018-99-111658

Published: 2018

Journal Articles

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Blood (2017) 130 (Supplement 1): 4323.

https://doi.org/10.1182/blood.V130.Suppl_1.4323.4323

Published: 2017

Journal Articles

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Ohad Benjamini, MD, David Lavie, MD, Eldad J Dann, MD, Chava Perry, MDPhD, Ory Rouvio, MD, Olga Shvetz, MD, Anatoly Nemets, MD, Ruth Perets, MD PhD, Revital Saban, MD, Avichai Shimoni, MD, Dina Ben-Yehuda, MD, Arnon Nagler, Abraham Avigdor, MD

Blood (2016) 128 (22): 3008.

https://doi.org/10.1182/blood.V128.22.3008.3008

Published: 2016

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Michal Abraham, PhD, Shiri Klein, Baruch Bulvik, Hanna Wald, Dvora Holam, Lola Weiss, Katia Beider, PhD, Orly Eizenberg, Ori Wald, MD PhD, Abraham Avigdor, MD, Ohad Benjamini, MD, Eithan Galun, MD, Arnon Nagler, Yaron Pereg, PhD, Amnon Peled, PhD

Blood (2016) 128 (22): 767.

https://doi.org/10.1182/blood.V128.22.767.767

Published: 2016

Journal Articles

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Eldar Priel, MD, Meirav Kedmi, MD, Tima Davidson, MD, Ginette Schiby, MD, Elena Ribakovsky, MD, Ohad Benjamini, MD, Arnon Nagler, MD MSc, Abraham Avigdor, MD

Blood (2015) 126 (23): 5025.

https://doi.org/10.1182/blood.V126.23.5025.5025

Published: 2015

Journal Articles

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Ohad Benjamini, MD, Hagop M Kantarjian, MD, Susan O'Brien, MD, Deborah Thomas, MD, Farhad Ravandi, MD, Preetesh Jain, MD, DM, PhD, Sherry Pierce, Gautam Borthakur, MBBS, Tapan M. Kadia, MD, Elias Jabbour, MD, Zeev Estrov, MD, Rajyalakshmi Luthra, Ph.D., Jorge E. Cortes, MD

Blood (2013) 122 (21): 2734.

https://doi.org/10.1182/blood.V122.21.2734.2734

Published: 2013

Journal Articles

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Preetesh Jain, MD, DM, PhD, Hagop Kantarjian, MD, Keyur P. Patel, MD, PhD, Elias Jabbour, MD, Naval Daver, MD, Sherry Pierce, Ohad Benjamini, MD, Gautam Borthakur, MD, Courtney D. DiNardo, MD, Stefan H. Faderl, MD, Farhad Ravandi, MD, Jorge E. Cortes, MD, Guillermo Garcia-Manero, MD, Tapan M. Kadia, MD

Blood (2013) 122 (21): 5231.

https://doi.org/10.1182/blood.V122.21.5231.5231

Published: 2013

Journal Articles

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Ohad Benjamini, MD, Uri Rozovski, MD, Preetesh Jain, MD, DM, PhD, William G. Wierda, MD, Susan O'Brien, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Stefan H. Faderl, MD, Elizabeth J Shpall, MD, Chitra M Hosing, MD, Issa F. Khouri, MD, Richard E Champlin, MD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2013) 122 (21): 2880.

https://doi.org/10.1182/blood.V122.21.2880.2880

Published: 2013

Journal Articles

Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib

Dominik Wodarz, Naveen Garg, Natalia L. Komarova, Ohad Benjamini, MD, Michael J. Keating, MD, William G. Wierda, M.D., Ph.D, Hagop M. Kantarjian, MD, Danelle F. James, MD, Susan M. O'Brien, MD, Jan A. Burger, MD, PhD

Blood (2013) 122 (21): 4166.

https://doi.org/10.1182/blood.V122.21.4166.4166

Published: 2013

Journal Articles

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Stefan Faderl, MD, Keyur P. Patel, MD, PhD, Guillermo Garcia Manero, Ohad Benjamini, MD, Gautam Borthakur, M.D., Naveen Pemmaraju, M.D., Tapan M. Kadia, M.D., Naval G. Daver, MD, Aziz Nazha, Rajyalakshmi Luthra, PhD, Sherry A. Pierce, RN, BS, Jorge E. Cortes, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2484.

https://doi.org/10.1182/blood.V120.21.2484.2484

Published: 2012

Journal Articles

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Susan Lerner, MS, Ohad Benjamini, MD, Xuemei Wang, MS, Michael J. Keating, MD

Blood (2012) 120 (21): 2900.

https://doi.org/10.1182/blood.V120.21.2900.2900

Published: 2012

Journal Articles

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Long Xuan Trinh, MD, Young Kwang Chae, MD, MPH, Preetesh Jain, MD, DM, PhD, Ohad Benjamini, MD, Xuemei Wang, MS, Susan Lerner, MS, William G. Wierda, MD, Ph.D., Zeev Estrov, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 3931.

https://doi.org/10.1182/blood.V120.21.3931.3931

Published: 2012

Journal Articles

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Ohad Benjamini, MD, Hagop M. Kantarjian, MD, Mary Beth Rios, RN, Elias Jabbour, MD, Susan O'Brien, M.D., Preetesh Jain, MD, DM, PhD, Stefan Faderl, MD, Guillermo Garcia-Manero, MD, Farhad Ravandi, MD, Gautam Borthakur, M.D., Alfonso Quintás-Cardama, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 3783.

https://doi.org/10.1182/blood.V120.21.3783.3783

Published: 2012

Journal Articles

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Preetesh Jain, MD, DM, PhD, Long Xuan Trinh, Ohad Benjamini, MD, Susan Lerner, MS, Xuemei Wang, MS, Alessandra Ferrajoli, MD, Jan A. Burger, MD, PhD, Zeev Estrov, MD, PhD, William G. Wierda, MD, PhD, Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Lynne V. Abruzzo, MD, PhD, Michael J. Keating, MD

Blood (2012) 120 (21): 2890.

https://doi.org/10.1182/blood.V120.21.2890.2890

Published: 2012

Journal Articles

Early Molecular and Cytogenetic Responses Predicts for Significantly Longer Event Free Survival (EFS) and Overall Survival (OS) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) – an Analysis of 4 Tyrosine Kinase Inhibitor (TKI) Modalities (standard dose imatinib, high dose imatinib, dasatinib and nilotinib)

Preetesh Jain, MD, DM, PhD, Hagop M. Kantarjian, MD, Aziz Nazha, Elias Jabbour, Alfonso Quintás-Cardama, MD, Ohad Benjamini, MD, Sherry A. Pierce, RN, BS, Marylou Cardenas-Turanzas, Srdan Verstovsek, MD, PhD, Gautam Borthakur, M.D., Farhad Ravandi, MD, Susan O'Brien, M.D., Jorge E. Cortes, MD

Blood (2012) 120 (21): 70.

https://doi.org/10.1182/blood.V120.21.70.70

Published: 2012

NARROW

Assessment By MRI T2*of Iron Accumulation and Removal in Transfusion Dependent MDS Patients

Progression of Follicular Lymphoma within 24 Months of First Treatment (POD -24) As a Predictor of Overall Survival - a Single Center Retrospective Analysis

Front-Line Treatment with Obinutuzumab ± Chlorambucil for Chronic Lymphocytic Leukemia in Real-World Clinical Practice: Results of a Multinational, Multicenter Study By Eric and Icllsg

Ibrutinib, Bendamustine, Rituximab Combination for Relapsed and Refractory Aggressive B Cell Lymphoma — Interim Analysis of Phase II Clinical Trial

Ibrutinib: A Risk Factor for Invasive Fungal Infections?

Real-Life Experience of Nivolumab in Heavily Pretreated Relapsed and Refractory Classical Hodgkin Lymphoma

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

The High Affinity CXCR4 Inhibitor, BL-8040, Induces Apoptosis of AML Blasts and Their Terminal Differentiation By Blocking AKT/ERK Survival Signals and Downregulating BCL-2, MCL-1 and Cyclin-D1 through Regulation of Mir-15a/16-1 Expression

Prognostic Value of Interim and End of Treatment FDG-PET/CT Scan Results in Adult Patients with Burkitt Lymphoma - a Retrospective Analysis of a Single Center Cohort

Combination Chemotherapy With Tyrosine Kinase Inhibitors Can Overcome Bcr-Abl Mutations In Acute Lymphoblastic Leukemia Or Blast Crisis CML

Incidence, Clinical Characteristics, and Prognostic Relevance Of Clonal T-Cell Receptor Positive (TCR + ) Populations In Patients With Myelodysplastic Syndrome (MDS)

Outcome Of Chronic Lymphocytic Leukemia (CLL) Patients That Failed Allogeneic Stem Cell Transplantation

Kinetics Of Chronic Lymphocytic Leukemia Cells In Tissues and Blood During Therapy With The BTK Inhibitor Ibrutinib

Mutant NPM1 is a Reliable marker of Minimal Residual leukemia in patients with Acute Myeloid Leukemia.

Second Cancers Affect the Clinical Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Frontline FCR-Based Therapy.

Statins Use Improves the Clinical Outcomes of Salvage Therapy in Relapsed/Refractory CLL

Patient (Pt)-Driven Discontinuation of Tyrosine Kinase Inhibitor Theray in Chronic Phase Chronic Myeloid Leukemia (CML) - Single Institution Experience

Deletion 11q Abnormality in Patients with Chronic Lymphocytic Leukemia (CLL) May Not Have Poor Clinical Outcomes and Bulky Disease (clinical and radiological) At Presentation – Clinical Characteristics of (n=172) Previously Untreated Patients with CLL and del11q Cytogenetic Abnormality.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only